Novel Therapeutic Strategy for Triple Negative Breast Cancer Targeting hERO1-Lα

被引：0
|
作者：
Wada, Asaka [1 ,2 ]
Hirohashi, Yoshihiko [1 ]
Kutomi, Goro [2 ]
Shima, Hiroaki
Murata, Kenji [3 ,4 ]
Kubo, Terufumi [1 ]
Tsukahara, Tomohide [3 ,5 ]
Tamura, Yasuaki [1 ,6 ]
Torigoe, Toshihiko
Takemasa, Ichiro [2 ]
机构：
[1] Sapporo Med Univ, Dept Pathol, Sch Med, Sapporo, Japan
[2] Sapporo Med Univ, Dept Surg, Surg Oncol & Sci, Sapporo, Japan
[3] Sapporo Med Univ, Dept Path, Sapporo, Japan
[4] Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Sapporo Med Univ, Dept Orthop Surg, Sapporo, Japan
[6] Hokkaido Univ, Dept Mol Therapeut, Sapporo, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2352
引用
收藏
页码：1486 / 1486
页数：1
相关论文
共 50 条
  • [21] Targeting of breast cancer with non-oncology drugs - possible novel therapeutic option for triple-negative breast cancer
    Liedtke, C.
    Yan, K.
    Wu, Y.
    Hortobagyi, G. N.
    Symmans, W. F.
    Valero, V.
    Goette, M.
    Kiesel, L.
    Pusztai, L.
    CANCER RESEARCH, 2009, 69 (02) : 192S - 192S
  • [22] Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
    Canonici, Alexandra
    Browne, Alacoque L.
    Ibrahim, Mohamed F. K.
    Fanning, Kevin P.
    Roche, Sandra
    Conlon, Neil T.
    O'Neill, Fiona
    Meiller, Justine
    Cremona, Mattia
    Morgan, Clare
    Hennessy, Bryan T.
    Eustace, Alex J.
    Solca, Flavio
    O'Donovan, Norma
    Crown, John
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [23] Targeting serum response factor as a novel therapeutic approach for triple-negative breast cancer.
    Prencipe, Maria
    Gonzalez, Claudia Aura
    Russell, Niamh
    Gallagher, William M.
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
    Jiangsheng Xu
    Yunhua Liu
    Yujing Li
    Hai Wang
    Samantha Stewart
    Kevin Van der Jeught
    Pranay Agarwal
    Yuntian Zhang
    Sheng Liu
    Gang Zhao
    Jun Wan
    Xiongbin Lu
    Xiaoming He
    Nature Nanotechnology, 2019, 14 : 496 - 496
  • [25] Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer
    Liu, Cui-Cui
    Chen, Lie
    Cai, Yu-Wen
    Chen, Yu-Fei
    Liu, Yi-Ming
    Zhou, Yu-Jie
    Shao, Zhi-Ming
    Yu, Ke-Da
    CELL REPORTS MEDICINE, 2024, 5 (02)
  • [26] Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
    Jiangsheng Xu
    Yunhua Liu
    Yujing Li
    Hai Wang
    Samantha Stewart
    Kevin Van der Jeught
    Pranay Agarwal
    Yuntian Zhang
    Sheng Liu
    Gang Zhao
    Jun Wan
    Xiongbin Lu
    Xiaoming He
    Nature Nanotechnology, 2020, 15 : 342 - 342
  • [27] YB1 is a novel therapeutic for the treatment of triple negative breast cancer tumors
    Wang, Wei
    El Khalki, Lamyae
    Zai, Neelum Yousaf
    Szpendyk, Justin
    Alkrekshi, Akram
    Su, Bin
    Sossey-Alaoui, Khalid
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Therapeutic potential of ERK5 targeting in triple negative breast cancer
    Jesus Ortiz-Ruiz, Maria
    Alvarez-Fernandez, Stela
    Parrott, Tracy
    Zaknoen, Sara
    Burrows, Francis J.
    Ocana, Alberto
    Pandiella, Atanasio
    Esparis-Ogando, Azucena
    ONCOTARGET, 2014, 5 (22) : 11308 - 11318
  • [29] Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
    Anestis, Aristomenis
    Karamouzis, Michalis V.
    Dalagiorgou, Georgia
    Papavassiliou, Athanasios G.
    CANCER TREATMENT REVIEWS, 2015, 41 (06) : 547 - 553
  • [30] Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer
    Wali, Vikram B.
    Patwardhan, Gauri A.
    Hatzis, Christos
    Pusztai, Lajos
    CANCER RESEARCH, 2017, 77
12345